EDS01 + paclitaxel + cisplatin

EDS01 + paclitaxel + cisplatin is a **combination regimen** consisting of EDS01 (identity not fully defined in the available data), paclitaxel, and cisplatin. Paclitaxel is a microtubule-stabilizing agent that disrupts cell division, while cisplatin is a platinum-based chemotherapeutic that forms DNA crosslinks and interferes with DNA replication and transcription. The combination is being investigated or used in oncology settings, especially for solid tumors such as advanced non-small-cell lung cancer and ovarian cancer, where paclitaxel and cisplatin are synergistic and considered standard chemotherapeutic agents[2][3]. The novel component EDS01 likely represents an investigational agent added to enhance efficacy, but no specific mechanism or developer information is present for EDS01 in the retrieved data.